L-arginine for Knee Osteoarthritis Patients
ConditionOsteoarthritis, Knee
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-80
SponsorXiangya Hospital of Central South University
About this trial
This study will examine the pain-relief efficacy and safety of L-arginine in knee OA patients.
Eligibility criteria
Qualifiers
Age between 40 and 80 years.
Knee OA according to the American College of Rheumatology (ACR) clinical criteria.
Knee pain lasting 3 months or longer and a score of 7 or greater on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (standardized to range from 0-20).
Kellgren-Lawrence (KL) grade 2 or 3.
Disqualifiers
Any use of NSAIDs or other analgesics in the past two weeks.
History of injections of corticosteroids in the past three months or hyaluronic acid in the past 6 months in the index knee.
History of arthroscopy or open surgery in the index knee in the past 12 months.
History of a knee replacement in the index knee or planning to receive such a procedure within 3 months.
Trial design
Treatments tested in this trial
- L-arginine tablet
- Placebo tablet
Treatment groups
340 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xiangya Hospital of Central South University
Lead sponsor
Massachusetts General Hospital
Collaborator
School of Medicine, University of Nottingham
Collaborator
Memorial University of Newfoundland
Collaborator
Source ClinicalTrials.gov